Syndax Operating Income from 2010 to 2025

SNDX Stock

USD 14.21 0.03 0.21%

Syndax Pharmaceuticals Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Syndax Pharmaceuticals generates from its operations. View All Fundamentals

Operating Income

First Reported

2012-12-31

Previous Quarter

-74.2 M

Current Value

-89.6 M

Quarterly Volatility

27.8 M

Yuan Drop

Covid

Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.1 K, Interest Expense of 227.2 K or Selling General Administrative of 65.6 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0198 or PTB Ratio of 2.59. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.

For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Latest Syndax Pharmaceuticals' Operating Income Growth Pattern

Below is the plot of the Operating Income of Syndax Pharmaceuticals over the last few years. Operating Income is the amount of profit realized from Syndax Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Syndax Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Syndax Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syndax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Syndax Operating Income Regression Statistics

	Arithmetic Mean	(71,639,767)
	Coefficient Of Variation	(112.29)
	Mean Deviation	62,869,679
	Median	(43,766,000)
	Standard Deviation	80,444,222
	Sample Variance	6471.3T
	Range	256.2M
	R-Value	(0.79)
	Mean Square Error	2589.9T
	R-Squared	0.63
	Significance	0.0003
	Slope	(13,373,663)
	Total Sum of Squares	97069.1T

Syndax Operating Income History

	2025	-196.6 M
	2024	-207 M
	2023	-230 M
	2022	-151.8 M
	2021	26.2 M
	2020	-71.4 M
	2019	-57.5 M

Other Fundumenentals of Syndax Pharmaceuticals

Non Operating Income Net Other

Syndax Pharmaceuticals Operating Income component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Property Plant Equipment	Capital Surpluse	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock	Long Term Debt Total
Total Assets		1.0	0.93	-0.95	-0.92	0.91	0.95	0.7	1.0	-0.64	0.99	0.95	0.59	0.59	0.72	0.6	0.82	0.87	0.98	0.81	0.9	0.93	0.91
Total Stockholder Equity	1.0		0.93	-0.94	-0.92	0.91	0.96	0.68	1.0	-0.66	0.99	0.95	0.59	0.61	0.72	0.6	0.82	0.88	0.98	0.8	0.9	0.93	0.91
Current Deferred Revenue	0.93	0.93		-0.83	-0.81	0.86	0.9	0.57	0.92	-0.51	0.92	0.84	0.45	0.7	0.54	0.4	0.86	0.76	0.95	0.87	0.84	0.88	0.91
Net Debt	-0.95	-0.94	-0.83		0.89	-0.92	-0.82	-0.75	-0.94	0.63	-0.93	-0.88	-0.58	-0.37	-0.69	-0.58	-0.74	-0.83	-0.92	-0.82	-0.86	-0.89	-0.86
Retained Earnings	-0.92	-0.92	-0.81	0.89		-0.89	-0.89	-0.73	-0.92	0.74	-0.93	-0.93	-0.75	-0.59	-0.87	-0.77	-0.88	-0.87	-0.84	-0.68	-0.8	-0.89	-0.77
Accounts Payable	0.91	0.91	0.86	-0.92	-0.89		0.79	0.71	0.91	-0.63	0.93	0.86	0.57	0.39	0.72	0.58	0.9	0.75	0.88	0.86	0.75	0.84	0.86
Short Term Investments	0.95	0.96	0.9	-0.82	-0.89	0.79		0.6	0.95	-0.66	0.94	0.94	0.62	0.79	0.73	0.63	0.8	0.88	0.92	0.66	0.88	0.91	0.83
Total Liab	0.7	0.68	0.57	-0.75	-0.73	0.71	0.6		0.7	-0.28	0.72	0.7	0.64	0.26	0.61	0.59	0.57	0.79	0.67	0.59	0.75	0.79	0.69
Total Current Assets	1.0	1.0	0.92	-0.94	-0.92	0.91	0.95	0.7		-0.65	0.99	0.95	0.6	0.6	0.73	0.6	0.81	0.88	0.98	0.8	0.9	0.93	0.9
Short Term Debt	-0.64	-0.66	-0.51	0.63	0.74	-0.63	-0.66	-0.28	-0.65		-0.65	-0.62	-0.45	-0.42	-0.61	-0.69	-0.61	-0.63	-0.56	-0.36	-0.55	-0.62	-0.51
Common Stock	0.99	0.99	0.92	-0.93	-0.93	0.93	0.94	0.72	0.99	-0.65		0.96	0.64	0.6	0.76	0.59	0.86	0.89	0.97	0.79	0.88	0.94	0.89
Net Tangible Assets	0.95	0.95	0.84	-0.88	-0.93	0.86	0.94	0.7	0.95	-0.62	0.96		0.79	0.62	0.86	0.66	0.82	0.89	0.9	0.67	0.85	0.9	0.83
Long Term Debt	0.59	0.59	0.45	-0.58	-0.75	0.57	0.62	0.64	0.6	-0.45	0.64	0.79		0.46	0.88	0.72	0.62	0.74	0.49	0.28	0.59	0.66	0.52
Net Receivables	0.59	0.61	0.7	-0.37	-0.59	0.39	0.79	0.26	0.6	-0.42	0.6	0.62	0.46		0.43	0.41	0.62	0.64	0.59	0.32	0.66	0.65	0.55
Deferred Long Term Liab	0.72	0.72	0.54	-0.69	-0.87	0.72	0.73	0.61	0.73	-0.61	0.76	0.86	0.88	0.43		0.85	0.75	0.7	0.59	0.41	0.54	0.65	0.56
Short Long Term Debt	0.6	0.6	0.4	-0.58	-0.77	0.58	0.63	0.59	0.6	-0.69	0.59	0.66	0.72	0.41	0.85		0.6	0.64	0.45	0.29	0.51	0.58	0.49
Property Plant Equipment	0.82	0.82	0.86	-0.74	-0.88	0.9	0.8	0.57	0.81	-0.61	0.86	0.82	0.62	0.62	0.75	0.6		0.69	0.76	0.75	0.65	0.78	0.77
Capital Surpluse	0.87	0.88	0.76	-0.83	-0.87	0.75	0.88	0.79	0.88	-0.63	0.89	0.89	0.74	0.64	0.7	0.64	0.69		0.85	0.53	0.95	0.97	0.82
Net Invested Capital	0.98	0.98	0.95	-0.92	-0.84	0.88	0.92	0.67	0.98	-0.56	0.97	0.9	0.49	0.59	0.59	0.45	0.76	0.85		0.83	0.91	0.93	0.92
Long Term Investments	0.81	0.8	0.87	-0.82	-0.68	0.86	0.66	0.59	0.8	-0.36	0.79	0.67	0.28	0.32	0.41	0.29	0.75	0.53	0.83		0.66	0.71	0.82
Net Working Capital	0.9	0.9	0.84	-0.86	-0.8	0.75	0.88	0.75	0.9	-0.55	0.88	0.85	0.59	0.66	0.54	0.51	0.65	0.95	0.91	0.66		0.97	0.88
Capital Stock	0.93	0.93	0.88	-0.89	-0.89	0.84	0.91	0.79	0.93	-0.62	0.94	0.9	0.66	0.65	0.65	0.58	0.78	0.97	0.93	0.71	0.97		0.9
Long Term Debt Total	0.91	0.91	0.91	-0.86	-0.77	0.86	0.83	0.69	0.9	-0.51	0.89	0.83	0.52	0.55	0.56	0.49	0.77	0.82	0.92	0.82	0.88	0.9

Click cells to compare fundamentals

About Syndax Pharmaceuticals Financial Statements

Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-207 M	-196.6 M
Non Operating Income Net Other	695.8 K	730.5 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Syndax Operating Income from 2010 to 2025

Latest Syndax Pharmaceuticals' Operating Income Growth Pattern

Syndax Operating Income Regression Statistics

Syndax Operating Income History

Other Fundumenentals of Syndax Pharmaceuticals

Syndax Pharmaceuticals Operating Income component correlations

About Syndax Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for Syndax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY